Fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer

Human Gene Therapy

Volumn 24, Issue 12, 2013, Pages 1029-1041

  Koski, Anniina ^a   Ahtinen, Helena ^b   Liljenback, Heidi ^b   Roivainen, Anne ^b   Koskela, Anu ^c   Oksanen, Minna ^a   Partanen, Kaarina ^c   Laasonen, Leena ^c   Kairemo, Kalevi ^c   Joensuu, Timo ^c   Hemminki, Akseli ^a,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Docrates Oncology Clinic   (Finland)

^d Oncos Therapeutics   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL CITRATE; FLUANISONE; FLUORODEOXYGLUCOSE F 18; MIDAZOLAM; ONCOLYTIC ADENOVIRUS; DIAGNOSTIC AGENT; ONCOLYTIC VIRUS; RADIOPHARMACEUTICAL AGENT;

ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE METER; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CHOROIDEAL MELANOMA; COLON CARCINOMA; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; ENDOMETRIAL LEIOMYOSARCOMA; FOLLOW UP; HAMSTER; HISTIOCYTOMA; HUMAN; INFLAMMATION; LEIOMYOSARCOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALIGN FIBROTIC HISTIOCYTOMA; MELANOMA; METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; RECTUM CARCINOMA; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR VOLUME; ADENOVIRUS; ANIMAL; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION STUDY; GENE THERAPY; GENETICS; ISOLATION AND PURIFICATION; NEOPLASM;

ADENOVIRIDAE; ANIMALS; CRICETINAE; FLUORODEOXYGLUCOSE F18; GENETIC THERAPY; HUMANS; NEOPLASMS; ONCOLYTIC VIRUSES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84890519990     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.123     Document Type: Article

References (36)

1. Arellano, M., and Lonial, S. (2008). Clinical uses of GM-CSF, a critical appraisal and update. Biologics 2, 13-27.
2. Bakhshi, S., Radhakrishnan, V., Sharma, P., et al. (2012). Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation-a prospective study. Radiology 262, 956-968.
3. Bramante, S., Pesonen, S., Diaconu, I., et al. (2012). Serotype chimeric oncolytic adenovirus coding for granulocytemacrophage colony-stimulating factor (GMCSF) for treatment of soft tissue sarcoma in rodents and humans. Mol. Ther. 20, S272.
4. Cerullo, V., Pesonen, S., Diaconu, I., et al. (2010). Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 70, 4297-4309.
5. Cerullo, V., Diaconu, I., Kangasniemi, L., et al. (2011). Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19, 1737-1746.
6. Dranoff, G. (2003). GM-CSF-secreting melanoma vaccines. Oncogene 22, 3188-3192. (Pubitemid 36713771)
7. Eager, R.M., and Nemunaitis, J. (2011). Clinical development directions in oncolytic viral therapy. Cancer Gene Ther. 18, 305-317.
8. Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247.
9. Focosi, D., Caracciolo, F., Galimberti, S., et al. (2008). False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma. Ann. Hematol. 87, 343-344.
10. Garber, K. (2006). China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98, 298-300.
11. Hemminki, O., Diaconu, I., Cerullo, V., et al. (2012). Ad3-hTERTE1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol. Ther. 20, 1821-1830.
12. Hoh, C.K. (2007). Clinical use of FDG PET. Nucl. Med. Biol. 34, 737-742. (Pubitemid 47503824)
13. Hoos, A., Eggermont, A.M., Janetzki, S., et al. (2010). Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 102, 1388-1397.
14. Kantoff, P.W., Higano, C.S., Shore, N.D., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422.
15. Koski, A., Kangasniemi, L., Escutenaire, S., et al. (2010). Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol. Ther. 18, 1874-1884.
16. Koski, A., Raki, M., Nokisalmi, P., et al. (2012). Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol. Ther. 20, 221-229.
17. Kumar, A., Kumar, R., Seenu, V., et al. (2009). The role of 18FFDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur. Radiol. 19, 1347-1357.
18. Liikanen, I., Hirvinen, M., Bramante, S., et al. (2012). Autophagy induced by oncolytic adenoviruses combined with temozolomide triggers antitumor immune responses preclinically and in cancer patients. Mol. Ther. 20, S217.
19. Nokisalmi, P., Pesonen, S., Escutenaire, S., et al. (2010). Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin. Cancer Res. 16, 3035-3043.
20. Nokisalmi, P., Koski, A., Kanerva, A., et al. (2011). Serial treatment of refractory cancer patients with GM-CSF expressing oncolytic adenovirus enhances immunological response and survival without compromising safety. Mol. Ther. 19, S31.
21. Pesonen, S., Nokisalmi, P., Escutenaire, S., et al. (2010). Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther. 17, 892-904.
22. Pesonen, S., Diaconu, I., Cerullo, V., et al. (2012a). Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGDD24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int. J. Cancer 130, 1937-1947.
23. Pesonen, S., Diaconu, I., Kangasniemi, L., et al. (2012b). Oncolytic immunotherapy of advanced solid tumors with a CD40Lexpressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 72, 1621-1631.
24. Prestwich, R.J., Errington, F., Diaz, R.M., et al. (2009). The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum. Gene Ther. 20, 1119-1132.
25. Radhakrishnan, V., Kumar, R., Malhotra, A., and Bakhshi, S. (2012). Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. J. Nucl. Med. 53, 191-198.
26. Rajecki, M., Raki, M., Escutenaire, S., et al. (2011). Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses. Mol. Pharm. 8, 93-103.
27. Raki, M., Sarkioja, M., Escutenaire, S., et al. (2011). Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J. Gene Med. 13, 253-261.
28. Ranki, T., Kangasniemi, L., Ahokas, P., et al. (2011). Preclinical and clinical evaluation of oncolytic immunotherapy with Ad5/3-E2F1-D24-GMCSF (CGTG-602), a GM-CSF producing adenovirus targeted to tumors on four levels. Mol. Ther. 20, S36.
29. Reid, T.R., Freeman, S., Post, L., et al. (2005). Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 12, 673-681. (Pubitemid 41045565)
30. Shreve, P.D., Anzai, Y., and Wahl, R.L. (1999). Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19, 61-77; quiz 150-151.
31. Sze, D.Y., Freeman, S.M., Slonim, S.M., et al. (2003). Intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J. Vasc. Interv. Radiol. 14, 279-290. (Pubitemid 36314756)
32. Sze, D.Y., Iagaru, A.H., Gambhir, S.S., et al. (2011). Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography. Hum. Gene Ther. 23, 91-97.
33. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205-216. (Pubitemid 30099779)
34. Wahl, R.L., Jacene, H., Kasamon, Y., and Lodge, M.A. (2009). From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50 Suppl 1, 122S-150S.
35. Wolchok, J.D., Hoos, A., O'day, S., et al. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420.
36. Young, H., Baum, R., Cremerius, U., et al. (1999). Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35, 1773-1782. (Pubitemid 29512308)